



Bacterial Membrane Nanoparticles as an Immunotherapy System for Cancer Treatment

[View U.S. Patent No. 11,096,899 in PDF format.](#)

WARF: P180331US02

Inventors: Shaoqin Gong, Zachary Morris, Mingzhou Ye, Ravi Patel, Paul Sondel

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing improved cancer immunotherapy treatments. UW–Madison researchers have engineered a novel nanoparticle that elicits an improved immune response in select melanomas for significant tumor suppression.

Overview

Cancer immunotherapy – a therapy that stimulates and employs the body’s own immune system – is one of the most promising new approaches for treating cancer. Despite its tremendous potential, it shows limited effectiveness on patients with immunogenically “cold” tumors, as these tumors remain “hidden” from immune cells. Radiation therapy has been shown to improve the immunotherapy by turning a “cold” tumor into a “hot” one, thereby highlighting tumor cells for immune cell recognition. Significant effort has gone into stimulating immune cells to recognize tumor cells, but available methods are limited and often result in modest therapeutic benefit.

The Invention

UW–Madison researchers have engineered a bacterial membrane-coated nanoparticle (BNP) capable of acting as a cancer treatment/vaccine. The BNP consists of a nanosized polyplex made up of a PC7A polymer, a CpG oligonucleotide inside the bacterial membrane and surface attached maleimide (Mal) groups. PC7A provides both a pH responsiveness, which allows for membrane interactions at neutral pH, and subsequent endosomal escape once internalized into the cell. CpG functions as an immunostimulatory molecule (as a toll-like receptor agonist). And Mal groups decorate the surface of the BNP to capture tumor remnants created by radiation treatment, accelerating cellular recognition of the tumor.

In combination with radiation therapy, the inventors show that BNP treatment led to significant tumor growth suppression and enhanced survival rate in a model of a B78 melanoma tumor, a hard cancer to treat. By enabling patients’ immune systems to recognize the unique antigens on their own tumors, this combination therapy may represent a universal approach to achieve personalized cancer immunotherapy using off-the-shelf agents.

Applications

- Improved recognition of host immunity during cancer immunotherapy

Key Benefits

- In combination with radiation, BNP suppresses tumor growth and improves survival rate in B78 melanoma mouse model.
- BNP has no observable systemic toxicity.
- BNP production is easier and more cost-effective than similar nanoparticle approaches.

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

Additional Information

OK



For More Information About the Inventors

- [Shaoqin Gong](#)
- [Zachary Morris](#)
- [Paul Sondel](#)

Publications

- [Patel et al. Development of an in situ Cancer Vaccine via Combinational Radiation and Bacterial Membrane Coated Nanoparticles. 2019. Advanced Materials 31\(43\), e1902626.](#)

Tech Fields

- [Therapeutics & Vaccines : Oncology](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

Figures




Figure 1. Schematic of the in situ vaccine effect elicited by combined RT + BNP. **A)** A schematic of how a BNP interacts with the TME to enhance APC uptake and activation. **B)** Schematic depiction of the in situ vaccine effect elicited by combined RT + BNP. After RT stimulates neoantigen release, BNP is intratumorally injected to capture antigens. The BNP-antigen complex then undergoes highly efficient APC uptake and immune response due to the TLR2 agonists present on the BNP's bacterial membrane coating. Once the BNP is endocytosed, CpG is released from the polyplex core and activates TLR-9, which is located at the inner membrane of the endosomes, thereby prompting APC maturation. PCTA, another component of the polyplex, facilitates the endosomal escape of neoantigens via membrane disruption. The neoantigens in cytosol are degraded into small peptides by proteasomes and presented by MHC complexes. Finally, the mature APCs present neoantigens to CD4⁺ and CD8⁺ T cells and secrete cytokines that activate cancer immunity. **C)** Composition of the BNP and the function of each BNP component.

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK

